Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142


[A meta-analysis of Symptom Checklist-90 assessment results in Chinese nurses].

Wang ZH, Ye Y, Shen Z, Sun LG, Hu L, Yu WL, Xu M, Sun ZF, Cheng JD, Sun X.

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2018 Feb 20;36(2):129-133. doi: 10.3760/cma.j.issn.1001-9391.2018.02.013. Chinese.


[Research Progress on Determination of Drowning Site].

Zhao J, Xu LW, Kang XD, Shi H, Liu C, Hu SL, Yang XY, Xu QY, Cheng JD, Ai M.

Fa Yi Xue Za Zhi. 2018 Feb;34(1):55-59. doi: 10.3969/j.issn.1004-5619.2018.01.011. Epub 2018 Feb 25. Review. Chinese.


Teaching forensic pathology to undergraduates at Zhongshan School of Medicine.

Zhou N, Wu QP, Su T, Zhao QH, Yin K, Zheng D, Zheng JJ, Huang L, Cheng JD.

Med Sci Law. 2018 Apr;58(2):109-114. doi: 10.1177/0025802418760044. Epub 2018 Feb 21.


Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Keam B, Takahashi K, Cheng JD, Bang YJ.

Cancer Sci. 2018 Mar;109(3):771-776. doi: 10.1111/cas.13480. Epub 2018 Feb 8.


[Research Progress of Sudden Cardiac Death in Forensic Medicine].

Zheng D, Yin K, Zheng JJ, Zhou N, Liu Y, Fu X, Cheng JD.

Fa Yi Xue Za Zhi. 2017 Oct;33(5):457-469. doi: 10.3969/j.issn.1004-5619.2017.05.002. Epub 2017 Oct 25. Review. Chinese.


[Research Progress of the Relationship between SUNDS and OSAHS].

Wu YD, Zhang LY, Cheng JD.

Fa Yi Xue Za Zhi. 2017 Feb;33(1):52-57. doi: 10.3969/j.issn.1004-5619.2017.01.013. Epub 2017 Feb 25. Review. Chinese.


Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR.

J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.


IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK.

J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.


Xyloketal B alleviates cerebral infarction and neurologic deficits in a mouse stroke model by suppressing the ROS/TLR4/NF-κB inflammatory signaling pathway.

Pan N, Lu LY, Li M, Wang GH, Sun FY, Sun HS, Wen XJ, Cheng JD, Chen JW, Pang JY, Liu J, Guan YY, Zhao LY, Chen WL, Wang GL.

Acta Pharmacol Sin. 2017 Sep;38(9):1236-1247. doi: 10.1038/aps.2017.22. Epub 2017 May 29.


LNK deficiency aggravates palmitate-induced preadipocyte apoptosis.

Du JY, Jin CC, Wang GH, Huang XQ, Cheng JD, Wen XJ, Zhao XM, Wang GL.

Biochem Biophys Res Commun. 2017 Aug 19;490(2):91-97. doi: 10.1016/j.bbrc.2017.05.057. Epub 2017 May 17.


Asymmetric Total Syntheses of (-)-α-Lycorane, (-)-Zephyranthine, and Formal Synthesis of (+)-Clivonine.

Chen YJ, Cai SL, Wang CC, Cheng JD, Kramer S, Sun XW.

Chem Asian J. 2017 Jun 19;12(12):1309-1313. doi: 10.1002/asia.201700555. Epub 2017 May 31.


Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.


A novel mutation in the STK11 gene causes heritable Peutz-Jeghers syndrome - a case report.

Chen JH, Zheng JJ, Guo Q, Liu C, Luo B, Tang SB, Cheng JD, Huang EW.

BMC Med Genet. 2017 Feb 23;18(1):19. doi: 10.1186/s12881-017-0373-z.


CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts.

Tang CM, Zhang M, Huang L, Hu ZQ, Zhu JN, Xiao Z, Zhang Z, Lin QX, Zheng XL, -Yang M, Wu SL, Cheng JD, Shan ZX.

Sci Rep. 2017 Jan 12;7:40342. doi: 10.1038/srep40342.


Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy.

Tang CM, Liu FZ, Zhu JN, Fu YH, Lin QX, Deng CY, Hu ZQ, Yang H, Zheng XL, Cheng JD, Wu SL, Shan ZX.

Sci Rep. 2016 Oct 31;6:36146. doi: 10.1038/srep36146.


Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas.

Gonzalez RS, Bagci P, Basturk O, Reid MD, Balci S, Knight JH, Kong SY, Memis B, Jang KT, Ohike N, Tajiri T, Bandyopadhyay S, Krasinskas AM, Kim GE, Cheng JD, Adsay NV.

Mod Pathol. 2016 Nov;29(11):1358-1369. doi: 10.1038/modpathol.2016.125. Epub 2016 Jul 29.


Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.


Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ.

Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.


Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L.

J Clin Oncol. 2016 Jul 20;34(21):2460-7. doi: 10.1200/JCO.2015.64.8931. Epub 2016 May 2.


Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.

Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA.

Am J Clin Oncol. 2017 Aug;40(4):393-398. doi: 10.1097/COC.0000000000000171.


Supplemental Content

Loading ...
Support Center